Idex Corporation (IEX) Revenue by Segment

Idex revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Idex's largest business segment was Health and Science Technologies, with $414.00 million or 45% of revenue, up 13.8% from a year earlier. Next: Fluid and Metering Technologies (34%) and Fire and Safety Diversified Products (21%).

By region, United States brought in 51%, Europe brought in 24% and Asia brought in 17% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Health and Science Technologies (+13.8%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Idex Corporation

IEXManufacturing and Production

United States

Manufacturing and Production

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Health and Science TechnologiesFluid and Metering TechnologiesFire and Safety Diversified Products

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Health and Science Technologies	USD 414.00M	45.0%	+13.8%
Fluid and Metering Technologies	USD 316.70M	34.4%	+2.0%
Fire and Safety Diversified Products	USD 189.90M	20.6%	-0.6%

Sum of items USD 920.60M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Health and Science Technologies	414.0M	397.4M	406.6M	380.1M	363.9M	340.1M	371.7M	309.9M	303.0M	309.4M	312.1M	312.7M	338.4M	350.3M	352.5M	344.3M	325.4M	314.6M	293.6M	301.6M	274.3M	249.5M	235.0M	219.7M	215.2M	223.5M	226.8M	229.0M	232.2M	224.7M	225.3M	222.4M	227.4M	221.1M	–	207.0M
Fluid and Metering Technologies	316.7M	301.3M	305.0M	316.8M	310.5M	290.2M	298.8M	300.6M	318.9M	313.5M	298.5M	300.5M	324.1M	321.1M	287.4M	307.4M	299.5M	271.9M	252.8M	251.3M	250.9M	243.0M	229.2M	220.6M	218.9M	226.7M	227.3M	240.8M	246.1M	242.3M	237.1M	239.1M	242.8M	232.3M	–	220.9M
Fire and Safety Diversified Products	189.9M	188.2M	187.5M	181.8M	191.0M	184.0M	192.4M	187.7M	185.3M	177.6M	178.3M	180.2M	183.7M	174.0M	170.8M	172.3M	171.2M	164.6M	168.4M	159.1M	160.8M	159.5M	150.5M	140.9M	127.1M	144.3M	152.0M	154.5M	163.8M	155.2M	151.7M	161.4M	164.2M	159.2M	–	146.6M

Idex revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Health and Science Technologies	$414.0M	$397.4M	$380.1M	$363.9M	45%
Fluid and Metering Technologies	$316.7M	$301.3M	$316.8M	$310.5M	34%
Fire and Safety Diversified Products	$189.9M	$188.2M	$181.8M	$191.0M	21%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Idex revenue by region, last 4 quarters

Region	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
United States	$467.1M	$457.1M	$459.2M	$435.8M	51%
Europe	$221.9M	$225.3M	$208.2M	$220.1M	24%
Asia	$156.2M	$135.7M	$137.6M	$141.1M	17%
Other Geographical Areas	$45.0M	$41.6M	$41.7M	$39.2M	5%
North America, Excluding United States	$31.8M	$28.5M	$33.3M	$31.5M	3%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Idex's business segments?

Health and Science Technologies, Fluid and Metering Technologies and Fire and Safety Diversified Products (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Idex?

Health and Science Technologies: $414.00 million, or 45% of revenue, in Q2 fiscal 2026.

Where does Idex make its money?

By region in Q2 fiscal 2026: United States (51%), Europe (24%), Asia (17%) and Other Geographical Areas (5%).

MoreIdex stock overview Idex financials Idex executive team Idex shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.